Skip to main content
Log in

Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT), and adjuvant chemotherapy has been accepted in high-risk CSI NSGCTT. Because of the late toxicity of standard radiotherapy in CSI testicular seminoma (SGCTT), this therapeutic approach has been accepted also in the management of CSI SGCTT. In the current study, we analyzed single-center experience with risk-adapted therapeutic approaches (active surveillance and adjuvant chemotherapy) in patients with CSI SGCTT.

Patients and methods

The study analyzed a total of 90 patients collected at a single center from April 2008 to March 2015 with CSI SGCTT who were stratified into two groups according to risk-adapted therapeutic approaches.

Results

In the group A (low-risk CSI SGCTT—no rete testis invasion, tumor size <4 cm, pT1 stage), which consisted of 74 patients who underwent surveillance, relapse occurred in seven (9.5 %) patients after a mean follow-up of 14.5 months. In the group B (high-risk CSI SGCTT—rete testis invasion, tumor size >4 cm or pT ≥ 2 stage), which consisted of 16 patients who were treated with adjuvant chemotherapy, relapse occurred in two (12.5 %) patients after a mean follow-up of 13.8 months. Overall survival of patients in both groups was 100 %. The statistically significant difference in progression-free survival between these two groups was not found.

Conclusions

Radiotherapy is currently not recommended as an adjuvant treatment in CSI SGCTT patients. The benefit of using risk-adapted therapeutic approaches in CSI SGCTTs patients is evident.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [Internet]. IARC, Lyon. http://globocan.iarc.fr

  2. Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ et al (2013) Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):25–32

    Article  Google Scholar 

  3. De Wit R, Fizazi K (2006) Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24:5482–5492

    Article  PubMed  Google Scholar 

  4. Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M et al (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838

    Article  CAS  PubMed  Google Scholar 

  5. Nichols CR, Roth B, Albers P, Einhorn LH, Foster R et al (2013) Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:3490–3493

    Article  PubMed  Google Scholar 

  6. Tandstad T, Smaaland T, Solberg A, Bremnes RM, Langberg CW et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the SWENOTECA study group. J Clin Oncol 29:719–725

    Article  PubMed  Google Scholar 

  7. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878–888

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Chung P, Daugaard G, Tyldesley S, Panzarella T, Kollmannsberger C et al (2010) Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 28:15s (Suppl); abstr. 4535

  9. Aparicio J, Maroto P, Del Muro XG, Guma J, Sanchez-Munoz A et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29:4677–4681

    Article  PubMed  Google Scholar 

  10. Oliver RTD, Mason MD, Mead GM, Von der Maase H, Rustin GJS et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300

    Article  CAS  PubMed  Google Scholar 

  11. Oliver RTD, Mead GM, Rustin GJ, Joffe JK, Aass N et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29:957–962

    Article  CAS  PubMed  Google Scholar 

  12. Krege S, Beyer J, Souchon R, Albers P, Albrecht W et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53:478–496

    Article  PubMed  Google Scholar 

  13. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G et al (2015) Guidelines on testicular cancer, EAU, Arnhem, The Netherlands, ISBN/EAN: 978-90-79754-80-9

  14. Chung P, Warde P (2006) Surveillance in stage I seminoma. Urol Oncol 24:75–79

    Article  PubMed  Google Scholar 

  15. Cohn-Cedermark G, Stahl O, Tandstad T (2015) Surveillance versus adjuvant therapy of clinical stage I testicular tumors—a review and the SWENOTECA experience. Andrology 3:102–110

    Article  CAS  PubMed  Google Scholar 

  16. Vaugh DJ (2015) Primum non nocere: active surveillance for cinical stage I testicular cancer. J Clin Oncol 33(1):9–12

    Article  Google Scholar 

  17. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G (2009) Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol 71:22–28

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Ondrusova.

Additional information

This publication is the result of the implementation of project APVV-0016-11 supported by the Slovak Research and Development Agency.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ondrusova, M., Ondrus, D., Miskovska, V. et al. Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy. Int Urol Nephrol 47, 1143–1147 (2015). https://doi.org/10.1007/s11255-015-1002-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1002-4

Keywords

Navigation